SOLIRIS

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK, United States.

Active ingredients

The drug SOLIRIS contains one active pharmaceutical ingredient (API):

1	Eculizumab UNII A3ULP0F556 - ECULIZUMAB
	Eculizumab is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.
	Read more about Eculizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SOLIRIS Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ01	Eculizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10182X, 10183Y, 10190H, 10191J, 10192K, 10194M, 10521R, 10525Y
BR	Câmara de Regulação do Mercado de Medicamentos	565517100000001
CA	Health Products and Food Branch	02322285
EE	Ravimiamet	1342011
ES	Centro de información online de medicamentos de la AEMPS	07393001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	102268
FR	Base de données publique des médicaments	61969188
GB	Medicines & Healthcare Products Regulatory Agency	118126
HK	Department of Health Drug Office	61188
IL	מִשְׂרַד הַבְּרִיאוּת	6725
IT	Agenzia del Farmaco	038083010
JP	医薬品医療機器総合機構	6399424A1023
LT	Valstybinė vaistų kontrolės tarnyba	1030813
NZ	Medicines and Medical Devices Safety Authority	14812
PL	Rejestru Produktów Leczniczych	100192746
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68259001
SG	Health Sciences Authority	14226P
TR	İlaç ve Tıbbi Cihaz Kurumu	8680131470013
US	FDA, National Drug Code	25682-001